Blood Disorders & Hematology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This Phase 3 study is evaluating whether teclistamab, alone or combined with lenalidomide, can improve maintenance treatment for adults newly diagnosed with multiple myeloma after receiving a stem cell transplant. If successful, this approach may help keep the disease under control longer and delay its return. The trial is actively recruiting participants worldwide and could expand treatment choices for patients early in their disease journey.

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

This Phase 3 trial is testing linvoseltamab, a new drug, against standard treatments in adults with newly diagnosed multiple myeloma who cannot undergo a stem cell transplant. The goal is to find out if linvoseltamab offers better results or fewer side effects. Results from this study could lead to new treatment options for patients who have limited choices due to transplant ineligibility.

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

This trial focuses on children and young adults aged 0 to 45 with acute lymphoblastic leukemia (ALL). It is testing new treatment plans that may improve survival and provide more personalized care based on individual disease characteristics. Recruiting across many European countries, this study hopes to offer better outcomes for a wide age range of patients newly diagnosed with ALL.

Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire

This Phase 4 study is working to improve early diagnosis and treatment of sickle cell disease in newborns using point of care testing in Côte d’Ivoire. Early detection and care could greatly reduce complications and deaths among infants with this condition. The trial focuses on babies up to six months old and aims to make screening and treatment more accessible in this region.

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This long-term study is assessing the safety of pirtobrutinib, a targeted oral therapy, in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously been treated with BTK inhibitors. If found to be safe and effective, pirtobrutinib could offer a new treatment option for patients who have limited choices after other therapies. The study plans to follow participants for about five years across multiple countries.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.